Restricted accessResearch articleFirst published online 2023-12
Letter to the Editor: Repurposing Tafenoquine as a Potential Inhibitor Against Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease via a Fluorescence Polarization Assay
AnirudhanV, LeeH, ChengH, et al.Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19. J Med Virol, 2021; 93(5):2722–2734; doi: 10.1002/jmv.26814
2.
AherfiS, PradinesB, DevauxC, et al.Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. Future Microbiol, 2021; 16:1341–1370; doi: 10.2217/fmb-2021-0019
3.
YanG, LiD, LinY, et al.Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors. Cell Biosci, 2021; 11(1):199; doi: 10.1186/s13578-021-00720-3
4.
ZhangJ, YanH, YanG, et al.Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay. STAR Protoc, 2022; 3(4):101794; doi: 10.1016/j.xpro.2022.101794
5.
YanH, ZhangR, YanG, et al.Production of a versatile SARS-CoV-2 main protease biosensor based on a dimerization-dependent red fluorescent protein. J Med Virol, 2023; 95(1):e28342; doi: 10.1002/jmv.28342
6.
DowGS, SmithBL. A phase II, double blind, placebo-controlled, randomized evaluation of the safety and efficacy of tafenoquine in patients with mild-moderate COVID-19 disease. New Microbes New Infect, 2022; 47:100986; doi: 10.1016/j.nmni.2022.100986
